Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

expense (22,889) (22,499)

Research and development expense (12,585) (12,312)

Total pre-tax charges for stock-

based compensation expense (41,988) (40,707)

Tax benefit 12,537 12,432

Stock-based compensation expense,

net of tax $(29,451) $(28,275)

Diluted earnings per share and diluted weighted average shares outstanding

for the three months ended March 31, 2008 and 2007 were computed according

to the provisions of FAS 123R.

(2) Includes a charge of $(69,900)K recorded in February 2008 representing

the premium paid to purchase five million shares of Isis

Pharmaceuticals, Inc. common stock.

(3) For the three months ended March 31, 2007, includes a pre-tax gain of

$10,848K related to the sale of our entire investment in the common

stock of Therapeutic Human Polyclonals, Inc. in March 2007, which had

a zero cost basis.

(4) All periods reflect the adoption of Emerging Issues Task Force Issue

No. 04-8, "The Effect of Contingently Convertible Debt on Diluted

Earnings Per Share," or EITF 04-8. As a result of the adoption of EITF

04-8, the 9,686K shares issuable upon conversion of our $690.0 million

in principal of 1.25% convertible senior notes, which were issued in

December 2003, are now included in diluted weighted average shares

outstanding for purposes of computing diluted earnings per share,

unless the effect would be anti-dilutive. In accordance with EITF 04-

8, interest and debt fees related to these notes of $1.9 million, net

of tax, for both the three months ended March 31, 2008 and 2007, have

been added back to net income and 9,686K shares have
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
(Date:8/28/2014)... 2014 Sterlitech is proud to announce ... its stable of products . These additional ... and include membrane filters with surface charges. ... demand for our membrane process testing equipment, and correspondingly, ... sheet membranes,” explains Sterlitech President Mark Spatz. “The ...
(Date:8/28/2014)... Fla. Exciting new work by a Florida State ... system that can take your temperature, emit white light, ... And, the molecule looks like a butterfly. , Biwu ... Biomedical Engineering in the FAMU-FSU College of Engineering, created ... but has continued to discover that his creation has ...
(Date:8/28/2014)... August 28, 2014 A new ... the world is available from Strategic Consulting, Inc., ... “ Industrial Microbiology Market Review, Fourth Edition: Global ... ” (IMMR—4) tracks and compares microbiology test volumes, ... America, Europe and Asia, and forecasts future volumes ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... their 2008 Annual,Meeting, shareholders of Spherix Incorporated (Nasdaq: SPEX ) ... Douglas T. Brown, Senior VP and Manager of Corporate Banking Government ... Cox, Jr., Principal, Asset Protection Company -- Claire L. Kruger, ... Spherix -- Gilbert V. Levin, Ph.D., Director of Science and ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Spherix Holds Annual Shareholders Meeting 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6
(Date:8/28/2014)... Ga. The support of peer groups and ... breastfeeding programs, according to recent University of Georgia ... in the Athens-Clarke County area determined that role ... outcomes of mothers of infants. , "Mothers who ... successful at breastfeeding," said study co-author Alex Anderson, ...
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has ... College of Sports Medicine,s Conference on Integrative Physiology ... Florida. These awards are meant to promote ... from underrepresented groups into the mainstream of the ... of young scientists at the American College of ...
(Date:8/28/2014)... kilometres of new roads will be built worldwide by ... last wildernesses, where they bring an influx of destructive ... ambitious study has created a ,global roadmap, for prioritising ... the competing demands of development and environmental protection. , ... estimates that natural importance of ecosystems and a ,road-benefits, ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... hosting a lecture and symposium Tuesday, March 10, through ... disastrous floods of summer 2008. "Living With Floods: ... symposium in The Forkenbrock Series on Public Policy. National ... floods to the psychological impact of displacement, from flood ...
... infection by intestinal worms a condition that affects more ... the immune system is more versatile than has long been ... of exploration in the search for treatments against autoimmune diseases ... own tissues. The findings, reported by scientists who performed ...
... about how to "grow your own organs" using stem cells ... has been elusive. A new report published in the March ... ) brings bioengineered organs a step closer, as scientists from ... they were able to use a "scaffolding" material extracted from ...
Cached Biology News:Public Policy Center hosts flood symposium March 10-12 2A worm-and-mouse tale: B cells deserve more respect 2A worm-and-mouse tale: B cells deserve more respect 3From stem cells to new organs: Stanford and NYU scientists cross threshold in regenerative medicine 2
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... fosmid (40kb), and large plasmid insert (10-20kb) ... BAC vector. On command 20-50 fold copy ... DNA purification. Available with blue-white screening (pEZ ... the highest insert stability. Kits include electrocompetent ...
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
UCP1/2/3 (FL-307)...
Biology Products: